For most of the twentieth century, inflammation was thought to fade away on its own — a passive dissipation as triggering signals diminished. Then in the early 2000s, Charles Serhan’s laboratory at Harvard identified a family of endogenous lipid mediators biosynthesized from omega-3 fatty acids that actively terminate inflammation through dedicated receptors. These molecules — resolvins, protectins, and maresins — don’t merely suppress inflammation like NSAIDs or corticosteroids; they orchestrate its resolution while promoting tissue repair. The implications reach across cardiovascular disease, neurodegeneration, and chronic pain.
What Are Specialized Pro-Resolving Mediators?
Specialized pro-resolving mediators (SPMs) are a family of endogenous bioactive lipids biosynthesized from polyunsaturated fatty acids — primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), with some members derived from arachidonic acid (lipoxins) and docosapentaenoic acid (DPA). The major SPM classes include resolvins (E-series from EPA, D-series from DHA), protectins (from DHA), maresins (from DHA), and lipoxins (from arachidonic acid).[1]
The conceptual breakthrough was recognizing that resolution of inflammation is not a passive process of decaying signals but an active, programmed biochemical event. Serhan and colleagues demonstrated this using lipid mediator lipidomics applied to self-resolving inflammatory exudates, identifying novel structures with potent anti-inflammatory and pro-resolution activity at picomolar to nanomolar concentrations.[1]
How SPMs Work
Biosynthetic Pathways: SPMs are produced through sequential oxygenation of EPA and DHA by lipoxygenase enzymes (15-LOX, 12-LOX, 5-LOX) and, in some cases, aspirin-acetylated COX-2. The pathway is cell-type specific and frequently involves transcellular biosynthesis — for example, neutrophil 5-LOX acting on intermediates produced by endothelial or platelet 15-LOX. This explains why SPM production is contextual, occurring at inflamed tissue interfaces rather than systemically.[1]
Receptor-Mediated Signaling: Unlike NSAIDs that block prostaglandin synthesis, SPMs act through specific G-protein-coupled receptors. Resolvin D1 binds GPR32 and ALX/FPR2; resolvin E1 binds ChemR23 (ERV1) and antagonizes the leukotriene B4 receptor BLT1; maresin 1 signals through LGR6. These receptors are expressed on neutrophils, macrophages, and other immune cells, and engagement triggers a defined transcriptional program of resolution.[2]
Efferocytosis Enhancement: A defining action of SPMs is stimulation of macrophage efferocytosis — the clearance of apoptotic neutrophils. This is critical because uncleared apoptotic cells undergo secondary necrosis and release damage-associated molecular patterns that perpetuate inflammation. SPMs simultaneously polarize macrophages from the pro-inflammatory M1 phenotype toward the reparative M2 phenotype.[2]
Neutrophil Trafficking: SPMs reduce further neutrophil recruitment to inflamed tissue without causing immunosuppression. This is mechanistically distinct from corticosteroids: SPMs limit excessive infiltration while preserving the host defense functions of resident immune cells. In animal models of bacterial infection, SPMs actually enhance bacterial clearance while reducing collateral tissue damage.[3]
Clinical Evidence
Cardiovascular Disease: The REDUCE-IT trial demonstrated that high-dose icosapent ethyl (purified EPA) reduced major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides. Mechanistic substudies have linked benefit at least in part to elevated production of E-series resolvins and other EPA-derived mediators, though direct measurement remains methodologically challenging.[4]
Periodontal Disease: Resolvin E1 has been studied extensively in periodontitis, where chronic non-resolving inflammation drives bone loss. In animal models, topical RvE1 reversed established periodontal disease and regenerated lost bone — an outcome not achievable with conventional anti-inflammatory therapy.[2]
Neuroinflammation: Neuroprotectin D1 (NPD1), a DHA-derived protectin, has been shown to protect neurons from oxidative stress and apoptosis in models of stroke, Alzheimer’s disease, and retinal degeneration. Bazan and colleagues demonstrated that NPD1 is synthesized in the retinal pigment epithelium and brain, where it downregulates pro-apoptotic Bcl-2 family members and inhibits NF-κB activation.[5]
Pain and Tissue Repair: SPMs reduce inflammatory and neuropathic pain in preclinical models through actions on both peripheral nociceptors and central glial cells. Maresin 1, in particular, accelerates tissue regeneration and resolves pain in models of post-surgical and chemotherapy-induced neuropathy.[3]
Safety Profile
Because SPMs are endogenous molecules produced in physiological resolution programs, their pharmacology differs fundamentally from classical anti-inflammatories. Preclinical studies have consistently shown efficacy at nanogram-per-kilogram doses without immunosuppression, gastrointestinal toxicity, or cardiovascular signals associated with NSAIDs and COX-2 inhibitors.
Most clinical experience to date involves the precursor omega-3 fatty acids EPA and DHA rather than the SPMs themselves. High-dose EPA preparations have a well-characterized safety profile, with the main signal being a modest increase in atrial fibrillation observed in some trials. Direct administration of synthetic SPMs remains largely investigational, with early human pharmacokinetic and tolerability data available for selected analogs.[4]
An important consideration is that SPM biosynthesis can be impaired by several common factors: low dietary omega-3 intake, COX-2 inhibition (which paradoxically blocks aspirin-triggered resolvin synthesis), aging, and obesity. This may explain why certain populations with adequate substrate still experience non-resolving inflammation — the enzymatic machinery itself is dysregulated.
SPMs vs Conventional Anti-Inflammatory Approaches
NSAIDs and Corticosteroids: Classical anti-inflammatories work by suppressing pro-inflammatory mediator production — blocking COX enzymes or broadly inhibiting immune cell activation. This stops inflammation but does not actively promote its resolution, and may even impair it: COX-2 inhibition blocks the lipid class switching required for SPM biosynthesis.
Biologics: Anti-TNF and anti-IL-6 therapies neutralize specific pro-inflammatory cytokines but carry infection risks because they globally suppress host defense. SPMs, by contrast, enhance bacterial clearance while limiting tissue damage — a fundamentally different therapeutic logic.
Omega-3 Supplementation: Standard fish oil supplementation provides EPA and DHA as substrate but does not guarantee SPM production, which depends on enzymatic capacity and inflammatory context. This may explain heterogeneous results in omega-3 trials and has motivated development of SPM-enriched preparations and direct SPM analogs.[4]
Therapeutic Implications: The SPM framework suggests that chronic inflammatory diseases — including atherosclerosis, neurodegeneration, and inflammatory bowel disease — may represent failures of resolution rather than excesses of initiation. If correct, this reframes treatment goals: rather than indefinitely suppressing inflammatory signaling, the aim becomes restoring the resolution program. Whether direct SPM administration or upstream pathway support proves more effective in humans remains the central question of ongoing clinical research.
References
- Serhan CN. “Pro-resolving lipid mediators are leads for resolution physiology.” Nature. 2014;510(7503):92-101.
- Serhan CN, Chiang N, Dalli J, Levy BD. “Lipid mediators in the resolution of inflammation.” Cold Spring Harbor Perspectives in Biology. 2015;7(2):a016311.
- Chiang N, Serhan CN. “Specialized pro-resolving mediator network: an update on production and actions.” Essays in Biochemistry. 2020;64(3):443-462.
- Bhatt DL, Steg PG, Miller M, et al. “Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.” New England Journal of Medicine. 2019;380(1):11-22.
- Bazan NG, Calandria JM, Serhan CN. “Rescue and repair during photoreceptor cell renewal mediated by docosahexaenoic acid-derived neuroprotectin D1.” Journal of Lipid Research. 2010;51(8):2018-2031.
